Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance.
active surveillance
beta-human-chorionic-gonadotropin
estrogens
menopause
micropapillary thyroid carcinoma
pregnancy
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
received:
09
05
2023
medline:
24
10
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
The effect of estrogen and beta-human chorionic gonadotropin on micropapillary thyroid carcinoma (mPTC) is not defined. Pregnancy and menopause could represent critical moments during active surveillance (AS) for women with mPTC. To evaluate the effect of either pregnancy or menopause on growth of mPTCs on AS. Women with mPTC on AS who became pregnant or underwent menopause during AS were evaluated in this retrospective observational study. The primary outcome was disease progression according to the AS protocol. The secondary outcome was the shrinkage of mPTCs. We compared the menopause group of patients with 2 unmatched control groups: (1) the pre-menopause group of patients on AS who had not experienced menopause yet and (2) the post-menopause group of patients who started AS while already in menopause. Five patients who became pregnant and 9 who underwent menopause during AS were enrolled. No patient from either group had a disease progression, and all pregnant patients showed stable disease after pregnancy. Four patients of the menopause group (44%) experienced mPTC shrinkage. The percentage of patients with mPTC shrinkage was significantly higher in the menopause group than in the 2 control groups. mPTC AS appears to be safe and feasible in patients who become pregnant or undergo menopause during surveillance. Our data suggest a possible association between menopause and mPTC shrinkage during AS.
Sections du résumé
Background
UNASSIGNED
The effect of estrogen and beta-human chorionic gonadotropin on micropapillary thyroid carcinoma (mPTC) is not defined. Pregnancy and menopause could represent critical moments during active surveillance (AS) for women with mPTC.
Objective
UNASSIGNED
To evaluate the effect of either pregnancy or menopause on growth of mPTCs on AS.
Patients and Methods
UNASSIGNED
Women with mPTC on AS who became pregnant or underwent menopause during AS were evaluated in this retrospective observational study. The primary outcome was disease progression according to the AS protocol. The secondary outcome was the shrinkage of mPTCs. We compared the menopause group of patients with 2 unmatched control groups: (1) the pre-menopause group of patients on AS who had not experienced menopause yet and (2) the post-menopause group of patients who started AS while already in menopause.
Results
UNASSIGNED
Five patients who became pregnant and 9 who underwent menopause during AS were enrolled. No patient from either group had a disease progression, and all pregnant patients showed stable disease after pregnancy. Four patients of the menopause group (44%) experienced mPTC shrinkage. The percentage of patients with mPTC shrinkage was significantly higher in the menopause group than in the 2 control groups.
Conclusions
UNASSIGNED
mPTC AS appears to be safe and feasible in patients who become pregnant or undergo menopause during surveillance. Our data suggest a possible association between menopause and mPTC shrinkage during AS.
Identifiants
pubmed: 37873501
doi: 10.1210/jendso/bvad109
pii: bvad109
pmc: PMC10590641
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvad109Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.
Références
Thyroid. 2014 May;24(5):840-4
pubmed: 24397849
Endocr Pathol. 2022 Mar;33(1):27-63
pubmed: 35288841
Surgery. 2018 Jan;163(1):143-149
pubmed: 29128169
JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1015-1020
pubmed: 28859191
Thyroid. 2019 Jul;29(7):956-962
pubmed: 31038017
Cancer Lett. 1994 Aug 29;84(1):59-66
pubmed: 7521273
J Clin Med. 2021 Sep 09;10(18):
pubmed: 34575179
Thyroid. 2016 Jan;26(1):156-60
pubmed: 26670937
Curr Cancer Drug Targets. 2008 Aug;8(5):367-77
pubmed: 18690843
Thyroid. 2022 Apr;32(4):351-367
pubmed: 35081743
J Endocrinol Invest. 2004 Jan;27(1):31-6
pubmed: 15053240
J Clin Endocrinol Metab. 2020 Mar 1;105(3):
pubmed: 31652318
Thyroid. 2010 Oct;20(10):1179-85
pubmed: 20860423
Thyroid. 1995 Oct;5(5):425-34
pubmed: 8563483
J Clin Endocrinol Metab. 1991 Oct;73(4):824-31
pubmed: 1909707
J Thyroid Res. 2011;2011:691719
pubmed: 21811666
J Clin Endocrinol Metab. 1998 Oct;83(10):3702-9
pubmed: 9768687
Thyroid. 2003 Apr;13(4):381-7
pubmed: 12804106
J Clin Oncol. 2016 Oct 20;34(30):3672-3679
pubmed: 27601555
Thyroid. 2017 Mar;27(3):315-389
pubmed: 28056690
Cancer. 1993 Aug 15;72(4):1364-8
pubmed: 8339226